148 related articles for article (PubMed ID: 9539780)
61. [Construction of expression vector for human-mouse chimeric antibody and expression of an antibody against human HER2].
Wang LL; Han H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):363-5. PubMed ID: 15193240
[TBL] [Abstract][Full Text] [Related]
62. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
63. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.
He X; Archer GE; Wikstrand CJ; Morrison SL; Zalutsky MR; Bigner DD; Batra SK
J Neuroimmunol; 1994 Jul; 52(2):127-37. PubMed ID: 7518471
[TBL] [Abstract][Full Text] [Related]
64. Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer.
Brakenhoff RH; van Gog FB; Looney JE; van Walsum M; Snow GB; van Dongen GA
Cancer Immunol Immunother; 1995 Mar; 40(3):191-200. PubMed ID: 7728778
[TBL] [Abstract][Full Text] [Related]
65. Antigen binding of an ovomucoid-specific antibody is affected by a carbohydrate chain located on the light chain variable region.
Fujimura Y; Tachibana H; Eto N; Yamada K
Biosci Biotechnol Biochem; 2000 Nov; 64(11):2298-305. PubMed ID: 11193395
[TBL] [Abstract][Full Text] [Related]
66. Establishment, molecular rescue, and expression of 123AV16-1, a tumor-reactive human monoclonal antibody.
Hall BL; Murray JH; Haspel MV; Kobrin BJ
Cancer Res; 1994 Oct; 54(19):5178-85. PubMed ID: 7923137
[TBL] [Abstract][Full Text] [Related]
67. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
Preston MJ; Gerçeker AA; Reff ME; Pier GB
Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
[TBL] [Abstract][Full Text] [Related]
68. Unusual amino acid usage in the variable regions of mercury-binding antibodies.
Westhoff CM; Lopez O; Goebel P; Carlson L; Carlson RR; Wagner FW; Schuster SM; Wylie DE
Proteins; 1999 Nov; 37(3):429-40. PubMed ID: 10591102
[TBL] [Abstract][Full Text] [Related]
69. Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody.
Tang Y; Beuerlein G; Pecht G; Chilton T; Huse WD; Watkins JD
J Biol Chem; 1999 Sep; 274(39):27371-8. PubMed ID: 10488067
[TBL] [Abstract][Full Text] [Related]
70. Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions.
Ill CR; Gonzales JN; Houtz EK; Ludwig JR; Melcher ED; Hale JE; Pourmand R; Keivens VM; Myers L; Beidler K; Stuart P; Cheng S; Radhakrishnan R
Protein Eng; 1997 Aug; 10(8):949-57. PubMed ID: 9415445
[TBL] [Abstract][Full Text] [Related]
71. Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody.
Calvo B; Kashmiri SV; Hutzell P; Hand PH; Slavin-Chiorini DC; Schlom J; Zaremba S
Cancer Biother; 1993; 8(1):95-109. PubMed ID: 7529083
[TBL] [Abstract][Full Text] [Related]
72. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities.
Babcook JS; Leslie KB; Olsen OA; Salmon RA; Schrader JW
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7843-8. PubMed ID: 8755564
[TBL] [Abstract][Full Text] [Related]
73. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.
Kolbinger F; Saldanha J; Hardman N; Bendig MM
Protein Eng; 1993 Nov; 6(8):971-80. PubMed ID: 8309946
[TBL] [Abstract][Full Text] [Related]
74. Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy.
Onuma E; Sato K; Saito H; Tsunenari T; Ishii K; Esaki K; Yabuta N; Wakahara Y; Yamada-Okabe H; Ogata E
Anticancer Res; 2004; 24(5A):2665-73. PubMed ID: 15517871
[TBL] [Abstract][Full Text] [Related]
75. Sequence analysis and bacterial production of the anti-c-myc antibody 9E10: the V(H) domain has an extended CDR-H3 and exhibits unusual solubility.
Schiweck W; Buxbaum B; Schätzlein C; Neiss HG; Skerra A
FEBS Lett; 1997 Sep; 414(1):33-8. PubMed ID: 9305727
[TBL] [Abstract][Full Text] [Related]
76. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
[TBL] [Abstract][Full Text] [Related]
77. Structural Organization of 6B9 Molecule, a Monoclonal Antibody Against Lycopene.
Petyaev IM; Alekseev KP; Tsibezov VV; Kostina LV; Kozlov AY; Kyle NH; Bashmakov YK
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):259-263. PubMed ID: 29267147
[TBL] [Abstract][Full Text] [Related]
78. Molecular characterization of a monoclonal murine anti-blood group A antibody.
Lévy M; Edelman L; Dighiero G
Immunol Lett; 2001 Feb; 76(1):15-23. PubMed ID: 11222908
[TBL] [Abstract][Full Text] [Related]
79. Production and characterization of a bacterial single-chain antibody fragment specific to B-cell-activating factor of the TNF family.
Cao P; Tang XM; Guan ZB; Diao ZY; Zhang SQ
Protein Expr Purif; 2005 Oct; 43(2):157-64. PubMed ID: 16023370
[TBL] [Abstract][Full Text] [Related]
80. Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor.
Papanastasiou D; Mamalaki A; Eliopoulos E; Poulas K; Liolitsas C; Tzartos SJ
J Neuroimmunol; 1999 Feb; 94(1-2):182-95. PubMed ID: 10376952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
